Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis.
Sepideh Tahsini TekantapehMorteza GhojazadehAli Akbar GhamariAida MohammadiHassan SoleimanpourPublished in: Expert review of respiratory medicine (2022)
Baricitinib prescription is strongly recommended in moderate to severe COVID-19.